Entacapone detection by a GOQDs-molecularly imprinted silica fluorescent chemical nanosensor
A sensitive fluorescent chemical nanosensor for the detection of entacapone (EN) in pharmaceutical samples is introduced. EN is a nitrocatechol drug that functions as a selective and reversible inhibitor of catechol-O-methyl transferase and is widely prescribed in the treatment of Parkinson disease. Molecularly imprinting technology and graphene oxide quantum dots (GOQDs) were employed in designing the EN fluorescent nanosensor. GOQDs were embedded into an inorganic polymer while the imprinting process occurred. The synthesized GOQDs-embedded silica molecularly imprinting polymer (SMIP) showed strong fluorescent emission at 450 nm by exciting at 360 nm. The fluorescence intensity of GOQDs-embedded SMIP was quenched effectively by adsorption of EN as a template molecule. The quenching corresponded to EN concentration in a linear range of at least 0.40–6.00 μM with a limit of detection of 0.31 μM. The designed chemical nanosensor was successfully applied to the analysis of entacapone in some pharmaceutical tablets also containing carbidopa and levodopa (RSD 3.8%).
KeywordsEntacapone Nanosensor Fluorescence detection Graphene quantum dots Inorganic molecularly imprinted polymer
The authors are grateful to the Research Council of University of Tehran for the financial support of this work.
Compliance with ethical standards
This research was performed in accordance with the Declaration of Helsinki and with approval of the ethics board of the University of Tehran. Human plasma sample used in this work was from a healthy volunteer with O-positive blood who signed an informed consent form in the Iranian Blood Transfusion Center. It was a fresh frozen plasma (Product Code: E070V00).
Conflict of interest
The authors declare that they have no conflicts of interest.
- 15.Ganjali MR, Faridbod F, Norouzi P. Biomimetic molecularly imprinted polymers as smart materials and future perspective in health care. Adv Health Mater 2014;465-492.Google Scholar
- 20.Chantada-Vázquez MP, Sánchez-González J, Peña-Vázquez E, Tabernero MJ, Bermejo AM, Bermejo-Barrera P, et al. Synthesis and characterization of novel molecularly imprinted polymer – coated Mn-doped ZnS quantum dots for specific fluorescent recognition of cocaine. Biosens. 2016;75:213–21.CrossRefGoogle Scholar
- 24.Brooks DJ, Agid Y, Eggert K, Widner H, Østergaard K, Holopainen A. Treatment of end-of-dose wearing-off in Parkinson’s disease: Stalevo® (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess®/Comtan® (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment. Europ Neurolog. 2005;53:197–202.CrossRefGoogle Scholar
- 32.Koradia SK, Jivani NP, Malaviya SV, Chauhan SP, Vaghani SS. Development and validation of spectrophotometric method for the estimation of entacapone in pharmaceutical formulations. Int J Chem Sci. 2009;7:349–52.Google Scholar
- 33.Ramaiyan S, Anubala S, Nagaiah K. Analytical methods for determination of entacapone in pharmaceuticals and urine. Eurasian J Anal Chem. 2015;10:150–62.Google Scholar